Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response.
about
First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.Diagnostic value of protein chips constructed by lung-cancer-associated markers selected by the T7 phage display libraryCaspase-cleaved cytokeratin-18 and tumour regression in gastro-oesophageal adenocarcinomas treated with neoadjuvant chemotherapy.Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer.Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.The M30 assay does not detect apoptosis in epithelial-derived cancer cells expressing low levels of cytokeratin 18.Anticancer bioactive peptide-3 inhibits human gastric cancer growth by suppressing gastric cancer stem cells.Plasma N-acetyl-glucosaminidase in advanced gastro-intestinal adenocarcinoma correlates with age, stage and outcome.Circulating cytokeratin 18 fragments and activation of dormant tumor cells in bone marrow of cancer patients.Serum programmed cell death protein 5 (PDCD5) levels is upregulated in liver diseases.MicroRNA profiles during galectin-9-induced apoptosis of pancreatic cancer cells.Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma.Serum cell death biomarker mirrors liver cancer regression after transarterial chemoembolisation.Effect of chymotrypsin C and related proteins on pancreatic cancer cell migration.A potential association between Helicobacter pylori CagA EPIYA and multimerization motifs with cytokeratin 18 cleavage rate during early apoptosis.Human chorionic gonadotropin decreases human breast cancer cell proliferation and promotes differentiation.The Role of Serum CK18, TIMP1, and MMP-9 Levels in Predicting R0 Resection in Patients with Gastric Cancer.
P2860
Q33639369-A733868F-D78F-4F2F-9B41-4B205FA0A71DQ33658526-67A35B4D-9C8E-4740-A978-FBA8AE38ABECQ35745779-FE84E840-DEAC-4E92-953E-24E9CFBE2FABQ35915297-762598D5-2FFC-4CBC-8209-3ACE7AAAF2B3Q35998447-7CD7C2AA-66A5-49E0-8764-11C538D02941Q36385291-818D997A-9A67-4DC5-A2F7-6DE4EF559136Q37724878-FA174D38-24EF-4E30-9412-0B68C23147D2Q38890416-7FF64813-6B92-4F79-9EF8-054B58AFB956Q39064767-45953C4E-E7B4-43AB-A6E4-74836215530DQ39157414-DCC4EE7B-F017-42D9-9B65-A0D4DE98E4E5Q41458358-C827CA27-ED18-4DE9-B7C8-4973D02A7E0FQ44724255-3A34DB04-BB5B-4644-9217-B230F8A7E3A9Q50224538-58A60CE8-AD8C-4C11-B800-E895FFB03FAFQ50893230-0A496C05-F492-4B96-8E3C-FAE386C96135Q51598731-5A8CC5FF-2AA8-4397-B4EF-94B75B42A65BQ51874385-465D0001-56F4-4B75-8D88-B66341CDD67BQ52629636-4BBDBC4C-D517-4021-88DC-7769FB7A4EB5Q54358345-DF33FA8E-9AB5-47B8-91FA-BC029A153C54Q55167424-D7845930-F0BF-4B70-9940-010B15BEA0AA
P2860
Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cytokeratin 18 in plasma of pa ...... biomarker of tumour response.
@en
Cytokeratin 18 in plasma of pa ...... biomarker of tumour response.
@nl
type
label
Cytokeratin 18 in plasma of pa ...... biomarker of tumour response.
@en
Cytokeratin 18 in plasma of pa ...... biomarker of tumour response.
@nl
prefLabel
Cytokeratin 18 in plasma of pa ...... biomarker of tumour response.
@en
Cytokeratin 18 in plasma of pa ...... biomarker of tumour response.
@nl
P2093
P2860
P356
P1476
Cytokeratin 18 in plasma of pa ...... biomarker of tumour response.
@en
P2093
T R J Evans
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605175
P407
P577
2009-07-14T00:00:00Z